Catalog: | C-FC-4035A |
Product Type: | FCM Antibody |
Size: | 50 µL/100 µL |
Reactivity: | Human |
Specificity: | Human FABP4Has cross-reactivity in ELISA withMouse FABP3No cross-reactivity in ELISA withHuman FABP6 |
Analysis mode: | IHC-P,FCM |
Host: | Rabbit |
Clonality: | Monoclonal |
Isotype: | IgG |
Alternate names: | fatty acid binding protein 4, adipocyte |
Form: | Liquid |
Shipping: | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Storage: | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Purification method: | Protein A |
Conjugation: | Unconjugated |
Immunogen: | Recombinant Human FABP4 / ALBP / A-FABP protein |
Buffer: | 0.2 μm filtered solution in PBS |
Application: | Early Mesodermal Lineage Markers |
Fatty acid-binding protein, adipocyte, also known as Adipocyte-type fatty acid-binding protein, Fatty acid-binding protein 4, Adipocyte lipid-binding protein, and FABP4, is a cytoplasm protein which belongs to thecalycin superfamily and Fatty-acid binding protein (FABP) family. In familial combined hyperlipidemia (FCHL), FABP4 correlated to body mass index (BMI), waist circumference and homeostasis model assessment (HOMA) index.FABP4 levels were associated with triglyceride-rich lipoproteins. In humans serum FABP4 levels correlate significantly with features of PCOS. It appears to be a determinant of atherogenic dyslipidemia. FABP4 pathway mediates the sebaceous gland hyperplasia in keratinocyte-specific Pten-null mice. FABP4 concentration significantly increased with an increasing of MS features and was strongly correlated with body-mass index, triglycerides, HDL-cholesterol concentrations and blood pressure. Patients in the highest quartile of FABP4 presented a six-fold increased odds ratio for MS and a three-fold increased odds for LD, adjusted by age, sex, body-mass index and the antiretroviral therapy. FABP4 is a strong plasma marker of metabolic disturbances in HIV-infected patients, and therefore, could serve to guide therapeutic intervention in this group of patients.
Copyright © 2025 Creative Biogene. All rights reserved.